Treace Medical Concepts, Inc. Net Fee Amt
Treace Medical Concepts, Inc. (TMCI) had Net Fee Amt of $957.81 as of 2026-05-08, per its S-8 filed 2026-05-08.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-08
- 2026-05-08: Net Fee Amt $957.81.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-08 | $957.81 S-8 · filed 2026-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |